Maravai LifeSciences Holdings Inc. Class A Common Stock vs Rush Street Interactive Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Rush Street Interactive Inc trades at $18.31 (market cap $2.14B). The key difference: Rush Street Interactive Inc is far larger — about 2.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Rush Street Interactive Inc for 13 Days on average.
| MRVI | RSI | |
|---|---|---|
Market Cap | $977.37M | $2.14B |
Volume | 2,742,564 | 1,828,735 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $34.52 |
52-Week Low | $2.83 | $15.89 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $1.08B | $1.80B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Rush Street Interactive (RSI) trades at $19.07, up 1.92% with mixed technical signals showing bearish moving averages but neutral RSI levels. The company reported strong Q2 2026 earnings with record revenue and adjusted EBITDA, beating expectations with $0.15 EPS versus $0.1499 forecast. Analyst consensus remains strongly bullish with 76.9% buy ratings and a $33.75 price target, representing 77% upside potential from current levels.
While technical indicators show near-term bearish pressure, strong fundamentals with 20.7% ROE and positive earnings momentum support long-term growth prospects. Key risks include competitive pressures in online gambling and market volatility, but institutional buying from BlackRock and Dimensional Fund Advisors signals confidence in the company's execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →